Hepatobiliary pathology

Current Opinion in Gastroenterology

Volumn 22, Issue 3, 2006, Pages 198-208

  Lefkowitch, Jay H ^a  

^a Columbia University ^*  (United States)

Author keywords

Iron; Liver biopsy; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Steatosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AMYLOID; ANTIBIOTIC AGENT; COPPER; CORTICOSTEROID; GEFITINIB; IMMUNOSUPPRESSIVE AGENT; IRON; KERATIN; TANNIN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FATTY LIVER; FIBROGENESIS; HEMOCHROMATOSIS; HEPATITIS C; HEPATOBILIARY DISEASE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER TUMOR; METABOLIC DISORDER; MICROSCOPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PEROXISOME; PORTAL VEIN; POSTOPERATIVE PERIOD; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SURGICAL TECHNIQUE; WILSON DISEASE;

AMYLOID; BILIARY TRACT DISEASES; BIOPSY; HUMANS; IRON OVERLOAD; KERATINS; LIVER DISEASES; LIVER TRANSPLANTATION; METABOLISM, INBORN ERRORS; MITOCHONDRIAL DISEASES; MUTATION; PEROXISOMES;

EID: 33746261446     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000218955.55688.af     Document Type: Review

References (97)

1. Teutsch HF. The modular microarchitecture of human liver. Hepatology 2005; 42:317-325. This elaborate alternative study of liver microanatomy discloses an organization into polyhedral primary modules with seven to nine facets that correlate most closely with classical lobules. The human primary module is more complex than that of the pig. The paper contains numerous images of the alkaline phosphatase-stained modular construct.
2. Braet F. How molecular microscopy revealed new insights into the dynamics of hepatic endothelial fenestrae in the past decade. Liver Int 2004; 24:532-539. An intriguing ultrastructural and conceptual journey into the formation and perturbation of endothelial fenestrae, including cycloheximide dry-cleavage imaging of fenestrae forming centers and their variations.
3. Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology 2005; 129:351-360. Among the many discussion points differentiating necrotic from apoptotic cell death is a review of various stress factors which lead to cytochrome c release from mitochondria and caspase 3 activation. An excellent summary diagram of apoptosis incorporates multi-organelle roles in this process.
4. Asano K, Tada S, Matsumoto T, et al. A novel bacterium Achromobacter xylosoxidans as a cause of liver abscess: three case reports. J Hepatol 2005; 43:362-365. Three cases of unusual post-cholecystectomy abscesses were presumably acquired via the biliary tree. This uncommon Gram-negative bacillus has also been isolated in urine, sputum, blood, cerebrospinal fluid, otopyrrhea and bile. The granulomatous nature of the histopathologic response, with central necrosis and a coral-like gross and computed tomography scan appearance are important diagnostic features.
5. Greenough TC, Carville A, Coderre J, et al. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am J Pathol 2005; 167:455-463. The progression of hepatic histological lesions from 2 to 7 days in marmosets inoculated with severe acute respiratory syndrome coronavirus (SARS-CoV) showed sinusoidal mononuclear cells, multifocal hepatitis and central venulitis in four of 11 animals with hepatic involvement.
6. Ding X, Xu F, Chen H, Tesh RB, Xiao S-Y. Apoptosis of hepatocytes caused by Punta Toro virus (Bunyaviridae: Phlebovirus) and its implication for phlebovirus pathogenesis. Am J Pathol 2005; 167:1043-1049.
7. Craig CE, Quaglia A, Dhillon AP. Extramedullary haematopoiesis in massive hepatic necrosis. Histopathology 2004; 45:518-525.
8. Moradpour D, Blum HE. A primer on the molecular virology of hepatitis C. Liver Int 2004; 24:519-525. This paper discusses the organization of the HCV genome and its encoded constituent structural and nonstructural protein products. A conceptual diagram of the intracellular life cycle of HCV is provided.
9. Shiha GE, Zalata KR, Abdalla AF, Mohamed MK. Immunohistochemical identification of HCV target antigen in paraffin-embedded liver tissue: reproducibility and staining patterns. Liver Int 2005; 25:254-260.
10. Kasprzak A, Seidel J, Biczysko W, et al. Intracellular localization of NS3 and C proteins in chronic hepatitis C. Liver Int 2005; 25:896-903.
11. Monto A, Dove LM, Bostrom A, et al. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C mono-infection. Hepatology 2005; 42:310-316.
12. Otani K, Korenaga M, Beard MR, et al. Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 2005; 128:96-107.
13. Wheeler M. Ethanol and HCV-induced cytotoxicity: the perfect storm. Gastroenterology 2005; 128:232-234.
14. Clouston AD, Powell EE, Walsh MJ, et al. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41:809-818. Hepatocyte regeneration in chronic hepatitis C is impaired (based on decreased expression of p21) and in combination with increased body mass index and steatosis results in stimuli provoking the ductular reaction, which in turn triggers fibrogenesis. The presence of a fine ductular reaction in chronic hepatitis C in Stage 0 patients implies that it precedes the development of fibrosis. The study did not entirely exclude the possibility that certain stimuli may co-promote both the ductular reaction and fibrosis.
15. Schulze-Krebs A, Preimel D, Popov Y, et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005; 129:246-258.
16. 1/S such as increased sensitivity to apoptosis, limitation of response to toxic injury by alcohol, steatosis or viral infection, and possible predilection for hepatocellular carcinoma.
17. Saitou Y, Shiraki K, Fuke H, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases. Hum Pathol 2005; 36:1066-1073.
18. Spangenberg HC, Viazov S, Kersting N, et al. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology 2005; 42:828-837.
19. Okanoue T, Makiyama A, Nakayama M, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005; 43:599-605.
20. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 42:838-845.
21. Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42:838-845.
22. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
23. Ghany MG, Doo E. Assessment of liver fibrosis: palpate, poke or pulse? Hepatology 2005; 42:759-761. The potential uses of elastography in liver disease other than chronic hepatitis C (e.g. NAFLD) are discussed, as are the drawbacks of current data.
24. Rousselet M-C, Michalak S, Dupré F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41:257-264. In the course of comparative scoring of chronic hepatitis C biopsies among different centers and pathologists of differing experience, specific histologic lesions which presented as problematic were seen as: the heterogeneous space distribution of lobular activity; an uncertain distinction between no portal fibrosis and mild portal fibrosis; true bridging fibrosis compared to normal portal tract extension; and incompletely represented septum located in the specimen periphery.
25. Almasio PL, Niero M, Angioli D, et al. Experts' opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.). J Hepatol 2005; 43:381-387. This intriguing study demonstrates differing viewpoints on the current clinical role of liver biopsy in managing patients with chronic hepatitis C. The authors urge that cost-benefit analysis be undertaken to address the added value of liver biopsy data to the clinical diagnosis and outcome of antiviral therapy. Since physicians manage similar patients with HCV infection very differently, determining the evidence-based value of liver biopsy data should help reduce these differences.
26. Herrine SK, Friedman LS. Divining the role of liver biopsy in hepatitis C. J Hepatol 2005; 43:374-376. The authors of this editorial discuss the limitations of a survey of brief clinical scenarios of patients with chronic hepatitis C in comparison to real-life decision-making, and features that were not addressed such as the role biopsy may play in advising against antiviral therapy as well as the perceived risk, low reimbursement and logistical difficulties (reasons not to biopsy, based on a US survey cited from 2002).
27. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005; 41:237-246.
28. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005; 43:901-910. A thorough review of several common herbal agents (Chinese herbs, pyrrolizidine alkaloids, Germander, Greater Celandine, Kava and Chaparral) and specific hepatotoxic lesions.
29. Herkel J, Schuchmann M, Tiegs G, Lohse AW. Immune-mediated liver injury. J Hepatol 2005; 42:920-923. This short review examines the basic CD8 targeting of cells with viral antigens in viral hepatitis, soluble liver antigen/liver-pancreas molecules in autoimmune hepatitis, concanavalin-A standing in as a possible model of idiosyncratic drug injury and immunologic cytoprotective factors such as interleukin-6-triggered amyloid A and chemokine KC, adiponectin, heme oxygenase-1, adenosine receptor antagonists and silencer of cytokine signalling-1 (SOCS-1).
30. Yamauchi K, Yamaguchi N, Furukawa T, et al. A murine model of acute liver injury induced by human monoclonal autoantibody. Hepatology 2005; 42:149-155.
31. Heneghan MA, McFarlane IG. Of mice and women: toward a mouse model of autoimmune hepatitis. Hepatology 2005; 42:17-20. This outstanding overview includes discussion of the several types of autoimmune hepatitis, the detectable autoantibodies (and the occasional presence in chronic hepatitis C of anti-liver-kidney microsomal-1 and anti-liver cytosol-1 autoantibodies) and an excellent figure summarizing the immune cells and cytokines involved in autoimmune hepatitis.
32. Marzioni M, Glaser S, Francis H, et al. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology 2005; 128:121-137. Immunohistochemistry, immunofluorescence and confocal microscopy were used to analyze expression of factors involved in serotonin-related up- and downregulation of bile flow and cholangiocyte proliferation.
33. Taffetani S, Ueno Y, Meng F, et al. Tannic acid inhibits cholangiocyte proliferation after bile duct ligation via a cyclic adenosine 5′,3′-monophosphate-dependent pathway. Am J Pathol 2005; 166:1671-1679.
34. Beaussier M, Wendum D, Fouassier L, et al. Adaptative bile duct proliferative response in experimental bile duct ischemia. J Hepatol 2005; 42:257-265.
35. Michalopoulos GK, Barua L, Bowen WC. Transdifferentiation of rat hepatocytes into biliary cells after bile duct ligation and toxic biliary injury. Hepatology 2005; 41:535-544.
36. Nozaki I, Lunz JG, Specht S, et al. Regulation and function of trefoil factor family 3 expression in the biliary tree. Am J Pathol 2004; 165:1907-1920.
37. Sato Y, Harada K, Kizawa K, et al. Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease. Am J Pathol 2005; 166:49-60.
38. Nathwani RA, Kumar SR, Reynolds TB, Kaplowitz N. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol 2005; 100:295-298.
39. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353:1261-1273. A review of the clinical and pathological findings and chief hypothesis on the disease pathogenesis.
40. Kamihara T, Shimoda S, Nakamura M, et al. Biliary epithelial cells regulate autoreactive T cells: implications for biliary-specific diseases. Hepatology 2005; 41:151-159.
41. Medina J, Sanz-Cameno P, García-Buey L, et al. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol 2005; 42:124-131.
42. Lykavieris P, Chardot C, Sokhn M, et al. Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver. Hepatology 2005; 41:366-371. Of 271 patients who underwent Kasai procedure for biliary atresia between 1968 and 1983, 63 survived for 20 years or more. Serum bilirubin was normal in 21 patients and 12 also had normal aspartate and alanine aminotransferases. Ultimately, fewer than 18% of those with Kasai survived without liver transplant, but required care for conditions such as bacterial cholangitis and complications of cirrhosis.
43. Sokol RJ, Mack CL. Optimizing outcomes and bridging biliary atresia into adulthood. Hepatology 2005; 41:231-233. An editorial comparing a French study showing 23% survivors of biliary atresia surgery with the better Japanese experience describes briefly the presentation of biliary atresia and the factors which appear to lead to improved long-term survival.
44. Carvalho E, Liu C, Shivakumar P, et al. Analysis of the biliary transcriptome in experimental biliary atresia. Gastroenterology 2005; 129:713-717. Biotinylated RNA pools were generated after intraperitoneal injection of rotavirus into Balb/c mice and then hybridized against microarrays with 45 101 gene products to analyze gene expression.
45. Pauli-Magnus C, Stieger B, Meier Y, et al. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol 2005; 43:342-357. An exceptionally comprehensive review of normal bile salt physiology, the roles of hepatocytes and bile duct cells in bile salt secretion and transport and model examples of cholestatic injury.
46. Balistreri WF, Bezerra JA, Jansen P, et al. Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases Single-Topic Conference. Hepatology 2005; 42:222-235. Experts discuss the molecular and develomental aspects of intrahepatic cholestasis. A detailed and useful table presents the gene defects and the disorders with which they are associated.
47. Libbrecht L, Spinner NB, Moore EC, et al. Peripheral bile duct paucity and cholestasis in the liver of a patient with Alagille syndrome. Further evidence supporting a lack of postnatal bile duct branching and elongation. Am J Surg Pathol 2005; 29:820-826. An elaborate light and immunohistochemical (cytokeratins 7 and 19) study examines the status of bile ducts in portal tracts from the central hilar region out to the periphery. A Jagged-1 mutation was present in tissue from both regions.
48. Cebecauerova D, Jirasek T, Budisova L, et al. Dual hereditary jaundice: simultaneous occurrence of mutations causing Gilbert's and Dubin-Johnson syndrome. Gastroenterology 2005; 129:315-320.
49. Noe J, Kullak-Ublick GA, Jochum W, et al. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J Hepatol 2005; 43:536-543.
50. Chen H-L, Chen H-L, Liu Y-J, et al. Developmental expression of canalicular transporter genes in human liver. J Hepatol 2005; 43:472-477.
51. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42:641-649. This study defines two types of NASH in pediatric NAFLD patients. Type 2 was the more common pattern, more often found in boys and in children of Asian, Native American and Hispanic ethnicity in this San Diego population. Lipogranulomas and glycogen nuclei were present in most patients. NAFLD in pediatrics therefore consists of three lesions: simple steatosis, type 1 NASH and type 2 NASH. In 16% of the patients the pattern was overlapping or indeterminate. There was no difference in laboratory values between types 1 and 2 NASH. Advanced fibrosis and cirrhosis were present in 8% of the group (eight patients).
52. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40:475-483. A study of liver biopsies from 195 morbidly obese subjects found prevalences of fatty liver only, isolated portal fibrosis and NASH of 30.3, 33.3 and 36.4%, respectively.
53. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413-1419.
54. ••] showed a predilection for portal fibrosis without prominent inflammation, ballooning and Mallory bodies as an important differentiating feature from adults, as well as a predilection for periportal (zone 1) fat. By multiple logistic regression, five features were independently associated with adult NASH; steatosis, liver-cell ballooning, lobular inflammation, fibrosis and absence of lipogranulomas.
55. Mendler MH, Kanel G, Govindarajan S. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int 2005; 25:294-304. This novel scoring and grading system selects certain features such as portal fibrosis and separates them out for individualized scoring, while combining scores for lobular inflammation, Mallory bodies, liver-cell ballooning and perisinusoidal fibrosis for the 'activity score'.
56. Franzén LE, Ekstedt M, Kechagias S, Bodin L. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. Modern Pathol 2005; 18:912-916.
57. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906. With two specimens obtained percutaneously from 51 NAFLD patients, there was an 18% discordance rate for hepatocyte ballooning and six of 17 patients with bridging fibrosis on one sample had only mild or no fibrosis on the other.
58. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42:132-138. In a series of 103 patients, of which at least half were receiving ursodeoxycholic acid or clofibrate, steatosis, inflammation, liver-cell ballooning and Mallory bodies improved overtime, but fibrosis advanced in at least one-third of patients (the latter slowly, with an average rate of fibrosis change of 0.02 ± 0.66 stages/year). Sampling error was considered among other reasons for the various changes between biopsies.
59. Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129:113-121.
60. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 2005; 42:44-52. This interesting population-based study of a predominantly Caucasian population examined methods of detecting NAFLD (including alanine aminotransferase, ultrasonography and age) and risk factors, with metabolic syndrome again more likely to predispose to this condition.
61. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42:5-13. The contribution of steatosis to liver disease, fibrosis and cirrhosis are examined in the context of HCV infection, alcoholic injury, oxidative stress, hepatic stellate cell activation, the ductular reaction and fibrogenesis; the possibility is mentioned of developing hepatocellular carcinoma because of age-related production of reactive oxygen species.
62. Saab S, Cho D, Lassman RC, et al. Recurrent non-alcoholic steatohepatitis in a living related liver transplant patient. J Hepatol 2005; 42:148-149.
63. Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int 2005; 25:760-771. A complex gene microarray study discusses the potential roles of many up-regulated (and several downregulated) genes in the pathogenesis of NASH. Comparison to obese and non-obese controls is also presented.
64. Ding X, Saxena NK, Lin S, et al. The roles of leptin and adiponectin. A novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005; 166:1655-1669. A complex study using real-time PCR, immunohistochemistry, picrosirius red staining and other methods to examine the fibrogenic effects after bile duct ligation in Zucker (fa/fa) rats which become diabetic and obese. Quiescent stellate cells as a source for protective adiponectin was demonstrated.
65. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41:753-760.
66. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42:928-940. An extensive review with 122 references covering normal background on mitochondrial function and the various mitochondrial insults in skeletal muscle, pancreatic β cells and the liver in NASH.
67. Zhou Z, Wang L, Song Z, et al. Zinc supplementation prevents alcoholic liver injury in mice through attenuation of oxidative stress. Am J Pathol 2005; 166:1681-1690. Both metallothionein-knockout and wild-type 129/Sv mice were fed an ethanol-containing liquid diet for 12 weeks with zinc supplementation to compare biochemical, immunohistochemical, ultrastructural and quantitative effects of adding zinc. Steatosis, mitochondrial enlargement and degeneration and rough endoplasmic reticulum disorganization were abrogated with zinc in a metallothionein-independent manner.
68. Beltroy EP, Richardson JA, Horton JD, et al. Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease. Hepatology 2005; 42:886-893. A murine model of Niemann-Pick type C disease is presented, along with the biochemical pathway of cholesterol uptake into hepatocytes from low-density lipoprotein, very-low-density lipoprotein remnant and chylomicron remnants via clathrin-coated pits. Progressive expansion of unesterified cholesterol trapped in late endosomal/lysosomal compartments is manifested as lipid on light microscopy in hepatocytes and in Kupffer cells, without excess collagen or glycogen, but with apoptosis.
69. Shneider BL, Rinaldo P, Emre S, et al. Abnormal concentrations of esterified carnitine in bile: a feature of pediatric acute liver failure with poor prognosis. Hepatology 2005; 41:717-721.
70. Alonso EM. Acute liver failure in children: the role of defects in fatty acid oxidation. Hepatology 2005; 41:696-699. This editorial discusses fatty acid oxidation defects as a possible cause of acute liver failure in children, the presentation being a scenario of nonketotic hypoglycemia following a minor febrile illness or fasting and dehydration. The author illustrates with a published heterozygous case with centrilobular necrosis and hemorrhage and microvesicular steatosis in the viable periportal hepatocytes.
71. Labarthe F, Dobbelaere D, Devisme L, et al. Clinical, biochemical and morphological features of hepatocerebral syndrome with mitochondrial DNA depletion due to deoxyguanosine kinase deficiency. J Hepatol 2005; 43:333-341. A 4-bp insertion in the deoxyguanosine kinase (DGOUK) gene resulted in early presentation prenatally with increased blood lactate, hypoglycemia and hyperammonemia. Deoxyguanosine kinase is involved in repleting intramitochondrial nucleoside pools for continued synthesis of mitochondrial DNA.
72. Chinnery PF, DiMauro S. Mitochondrial hepatopathies. J Hepatol 2005; 43:207-209. Some of the problems in diagnosis and presentation of mitochondrial hepatopathies are discussed in this editorial which cites the figure of approximately 1 in 20 000 children under 16 being affected by mitochondrial respiratory chain diseases, with approximately one in five having liver involvement.
73. Ku N-O, Lim JK, Krams SM, et al. Keratins as susceptibility genes for end-stage liver disease. Gastroenterology 2005; 129:885-893.
74. Zhou Q, Ji Z, Chen L, et al. Keratin mutation primes mouse liver to oxidative injury. Hepatology 2005; 41:517-525.
75. Lim EM, Rossi E, De Boer WB, et al. Hepatic iron loading in patients with compound heterozygous HFE mutations. Liver Int 2005; 24:631-636.
76. Butensky E, Fischer R, Hudes M, et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol 2005; 123:146-152.
77. Eng SC, Taylor SL, Reyes V, et al. Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis. Liver Int 2005; 25:513-517.
78. Pérez-Aguilar F, Burguera JA, Benlloch S, et al. Aceruloplasminemia in an asymptomatic patient with a new mutation. Diagnosis and family genetic analysis. J Hepatol 2005; 42:947-949.
79. Pietrangelo A, Caleffi A, Henrion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128:470-479. Those interested in the pathogenesis of primary iron-overload diseases and the role of hepcidin with HFE, HJR, TfR2 and other regulatory genes will find the three cases presented in this paper exceptionally intriguing, particularly a model presented in which hepcidin acts as the 'master controller' in mediating normal and abnormal iron metabolism.
80. Koyama C, Hayashi H, Wakusawa S, et al. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol 2005; 43:740-742.
81. Zoller H, McFarlane I, Theurl I, et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology 2005; 42:466-472. This report of seven cases of ferroportin 1 (hemochromatosis type 4) disease discusses possible explanations for increased prohepcidin levels in these patients with increased iron absorption, including mention of the postulated 'erythroid regulator', as yet unidentified, which may induce iron absorption.
82. Montosi G, Corradini E, Garuti C, et al. Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload. Hepatology 2005; 41:545-552.
83. Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 2005; 41:668-670.
84. Perri RE, Hahn SH, Ferber MJ, Kamath PS. Wilson disease - keeping the bar for diagnosis raised. Hepatology 2005; 42:974.
85. Agaram N, Shia J, Klimstra DS, et al. Globular hepatic amyloid: a diagnostic peculiarity that bears clinical significance. Hum Pathol 2005; 36:845-849.
86. Dirkx R, Vanhorebeek I, Martens K, et al. Absence of peroxisomes in mouse hepatocytes causes mitochondrial and ER abnormalities. Hepatology 2005; 41:868-878. This report details the ultrastructural changes in lysosomes, bile canaliculi and, importantly, in mitochondrial inner membranes along with the status of complex I, III and V and the redox state of the liver in a knockout mouse without peroxisomes.
87. Bioulac-Sage P, Rebouissou S, Cunha AS, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005; 128:1211-1218. The telangiectatic focal nodular hyperplasia is a morphologic lesion prone to hemorrhage which has features of both focal nodular hyperplasia (abnormal arterial structures and ductular reaction) and adenoma (hyperplastic parenchyma, sinusoidal dilatation and frequent multiplicity of lesions). This paper details clonality and genomic studies which differentiate these lesions.
88. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005; 25:16-27. Detailed descriptions of a range of lesions, including small-cell and large-cell dysplasia, low-grade and high-grade dysplastic nodules and foci of altered hepatocytes, are provided with thoughtful analysis of genomic characteristics which designate the true precursors of hepatocellular carcinoma. Helpful gross and microscopic images accompany the text.
89. Matsuura S, Aishima S, Taguchi K, et al. 'Scirrhous' type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology 2005; 47:382-390. The defining characteristics of scirrhous hepatocellular carcinoma are provided, including multinodularity of the lesion, entrapment of normal portal tracts within the sclerosis and significantly higher expression of cytokeratin 7 and lower expression of hepatocyte paraffin 1 (hep par 1) on immunohistochemistry.
90. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128:620-626.
91. Sebagh M, Yilmaz F, Karam V, et al. The histologic pattern of "biliary tract pathology" is accurate for the diagnosis of biliary complications. Am J Surg Pathol 2005; 29:318-323. Biliary tract obstructive features were found in 21% of 248 post-liver transplantation liver biopsies from 94 patients at a median of 28 days and a cause, particularly biliary obstruction, was found in 86%.
92. Fung J, Kelly D, Kadry Z, et al. Immunosuppression in liver transplantation. Beyond calcineurin inhibitors. Liver Transpl 2005; 11:267-280. This review covers the spectrum of immunosuppression agents used in liver transplantation and includes a particularly useful diagram of the target sites (from antigen presentation to T-cell binding and calcineurin-mediated interleukin 2-gene promotion to interleukin 2-receptor signaling) at which each agent acts.
93. Ahmed El-Refaie AM, Burt AD. Mast cells and c-Kit expression in liver allograft rejection. Histopathology 2005; 47:375-381.
94. Nadalin S, Malagó M, Valentin-Gamazo C, et al. Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefits. Liver Transpl 2005; 11:980-986.
95. Russo MW, Firpi RJ, Nelson DR, et al. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl 2005; 11:1235-1241.
96. Gawrieh S, Papouchado BG, Burgart LJ, et al. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005; 11:1207-1213.
97. Demetris AJ, Lunz JG. Early HCV-associated stellate cell activation in aggressive recurrent HCV: what can liver allografts teach about HCV pathogenesis? Liver Transpl 2005; 11:1172-1176.